Mandate

Vinge has advised Procuritas in connection with its investment in Strandberg Guitars

Vinge has advised Procuritas in connection with its investment in Strandberg Guitars, the global market leader in headless guitars under the .strandberg* brand.

Founded in 2012 by Ola Strandberg, Strandberg Guitars has established itself as the leading brand globally in headless guitars, a fast-growing niche in the electric guitar market. Headquartered in Uppsala, Sweden with local operations in California, USA the Company serves its global customer base directly online and through a wide network of renowned music retailers. Through its well-developed digital platform, Strandberg Guitars has built a large and highly engaged community of followers and musicians around the world. Since inception, the Company has had an uncompromised commitment to innovation aimed to lead the development of high-performance guitars that meet the needs of modern guitarists.

Vinge’s team consisted of, among others, Jonas Bergström, Jonas Johansson, Anna Jonsson, Carl Sander, Eléonore Friberg, Carl Trolle Olson and Alice Clarin (M&A), Lisa Hörnqvist, Karolina Fuhrman and Cecilia Cronqvist (Corporate Commercial and IT), Malin Malm Waerme and Arvid Axelryd (IP), Karin Gynnerstedt, Ebba Svenburg and Carl Östlund (Employment) and Erik Ax.

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025